Trial Profile
A Muticenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single-Dose of COL-1077 in Women Undergoing Transvaginal Pipelle-Directed Endometrial Biopsy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Sep 2016
Price :
$35
*
At a glance
- Drugs Lidocaine (Primary)
- Indications Procedural pain
- Focus Therapeutic Use
- Sponsors Juniper Pharmaceuticals
- 17 Aug 2016 Primary endpoint has not been met "Pain Intensity recorded on the 11-point NPRS" according to a Juniper Pharmaceuticals media release.
- 17 Aug 2016 According to a Juniper Pharmaceuticals media release, the development of COL-1077 was discontinued based on the results of this study.
- 04 Aug 2016 According to a Juniper Pharmaceuticals media release, the company anticipates to report top-line results from this trial by Sep 2016.